Clinical characteristics
| Characteristic | All, n = 57 | Probenecid Monotherapy, n = 30 | Combination Therapy, n = 27 | p* |
|---|---|---|---|---|
| Age, yrs, mean (SD) | 57 (16) | 59 (17) | 54 (14) | 0.23 |
| Male, n (%) | 44 (77) | 17 (57) | 27 (100) | < 0.001 |
| Ethnicity, n (%) | ||||
| Maori or Pacific | 31 (54) | 15 (50) | 16 (59) | 0.48 |
| Non-Polynesian | 26 (46) | 15 (50) | 11 (40) | |
| Tophaceous gout, n (%) | 34 (60) | 16 (53) | 18 (67) | 0.31 |
| Serum creatinine, μmol/l, mean (SD) | 114 (32) | 110 (33) | 117 (31) | 0.41 |
| eGFR, ml/min/1.73 m2, mean (SD) | 61.0 (20.2) | 59.7 (19.6) | 62.4 (21.1) | 0.61 |
| Baseline serum urate, mmol/l** | 0.60 (0.09) | 0.58 (0.09) | 0.63 (0.09) | 0.041 |
| Allopurinol dose, mg/day, mean (SD) | — | 0 (0) | 362 (124) | < 0.001 |
| Serum urate on allopurinol monotherapy, mmol/l, mean (SD) | — | — | 0.50 (0.11) | — |
| Probenecid dose, g/day, mean (SD) | 1.15 (0.59) | 1.29 (0.68) | 0.99 (0.44) | 0.056 |